At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 609 enrolled
Drug / intervention
MEDI3506 +2 moredrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects With Diabetic Kidney Disease
In Brief
A Phase 2 clinical trial evaluating MEDI3506, Placebo, and 1 other intervention for Diabetic Kidney Disease. Completed, enrolled 609 participants across 97 sites in 7 countries.
Detailed Summary
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Kidney Disease
CountriesArgentina, Canada, Chile, Japan, Peru, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartNov 2019
First PostedNov 2019
Primary CompletionMay 2023
TodayJul 2026
First PostedNov 20, 2019
Enrollment StartNov 18, 2019
Primary CompletionMay 16, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.6 years ago
Interventions
MEDI3506drug
Dose 1, Dose 2, Dose 3, Dose 4
Placebodrug
Placebo
Dapagliflozindrug
Dapagliflozin 10 mg